Peptides presented by class I major histocompatibility complex (MHC) molecules and derived from normal self-proteins that are expressed at elevated levels by cells from a variety of human (Hu) malignancies provide, in theory, potential target antigens for a broadspectrum, cytotoxic T lymphocyte (CTL)-based immunotherapy of cancer and hematologic malignancies. However, as such tumor-and leukemia-associated self-proteins are also expressed at low levels in some types of normal tissues, such as thymus, spleen and lymphohemopoietic cells, these self-MHC-self-peptide complexes may also represent thymic and/or peripheral tolerogens, thereby preventing immune responses. This is particularly true for class I MHC-peptide complexes expressed by bone marrow-derived cells in the thymus, as such expression would cause negative selection of immature thymic T cells with high avidity for self-MHC-self-peptide complexes. This intrathymic deletion of potentially self-reactive T cells could result in a peripheral T cell repertoire purged of CTL precursors with sufficient avidity to recognize natural tumor associated self-epitopes presented by class I MHC molecules on tumor cells. HLA-transgenic (Tg) mice provide the basis of an experimental strategy that exploits species differences between Hu and murine (Mu) protein sequences in order to circumvent self-tolerance and obtain HLArestricted CTL specific for epitopes derived from tumor-and leukemia-associated Hu self proteins, such as p53, Her-2/neu, hdm2 and CD19. Bone Marrow Transplantation (2000) 25, Suppl. 2, S43-S45. Keywords: CTL; p53; hdm2; CD19; TCR The p53 tumor suppressor protein and the hdm2 oncoprotein are frequently overexpressed in a wide variety of human malignancies, including acute myeloid and lymphoblastic leukemia (hdm2). Synthetic peptides representative of wild-type (wt) p53 and hdm2 sequences were tested for their binding to A2.1. HLA-A2.1(/K b )-Tg mice were immunized with A2.1-binding wt p53 and hdm2 peptides in order to induce A2.1-restricted and peptide-specific CTL. A2.1-restricted CTL lines obtained from both A2.1 and HuCD8 × A2.1(/K b )-Tg mice were able to recognize synCorrespondence: PD Dr M Theobald, Johannes-Gutenberg Universität Mainz, Langenbeckstr. 1, D-55131 Mainz, Germany thetic peptides representative of wt p53 and hdm2 sequences. These CTL were capable of recognizing and lysing Saos-2 cells transfected with p53 or hdm2 genes as opposed to the parental cell line that lacks any detectable p53 and hdm2 expression, thereby indicating that the antigenic peptides are being naturally processed and presented by A2.1. The identity of the naturally presented wt p53 and hdm2-derived CTL epitopes and the synthetic p53 and hdm2 peptides was confirmed by extracting peptides from class I MHC molecules of p53 and hdm2 transfectants. Subsequent HPLC purification allowed the reconstitution of CTL lysis by those natural and synthetic HPLC fractions which had an identical retention time. CTL specific for the identified wt p53 and hdm2 epitopes were of sufficiently high avidity to specifically kill a broad range of A2.1 + human tumor, leukemia, and myeloma targets provided that these cells displayed high level p53 and hdm2 protein expression as ascertained by Western blotting. In contrast, a variety of non-transformed human cells, such as PBMC, resting T and B cells, and antigen-activated T lymphocytes, all of them not expressing detectable amounts of p53 and hdm2, were not susceptible to lysis by these CTL. The full length ␣ and ␤ chains of high affinity T cell receptors (TCRs) derived from A2.1-restricted murine CTL clones have been cloned and sequenced. Hu A2.1-positive dendritic cells pulsed with the leukemia-associated hdm2 selfepitope were able to induce peptide-specific autologous human CTL. These autologous CTL, however, appeared to be of low avidity, thereby indicating that the hdm2 epitope does represent a self-tolerogen for high avidity CTL in vivo. Similar observations have been made for A2.1-presented wt p53 CTL epitopes.
The p53 tumor suppressor protein and the hdm2 oncoprotein are frequently overexpressed in a wide variety of human malignancies, including acute myeloid and lymphoblastic leukemia (hdm2). Synthetic peptides representative of wild-type (wt) p53 and hdm2 sequences were tested for their binding to A2. thetic peptides representative of wt p53 and hdm2 sequences. These CTL were capable of recognizing and lysing Saos-2 cells transfected with p53 or hdm2 genes as opposed to the parental cell line that lacks any detectable p53 and hdm2 expression, thereby indicating that the antigenic peptides are being naturally processed and presented by A2.1. The identity of the naturally presented wt p53 and hdm2-derived CTL epitopes and the synthetic p53 and hdm2 peptides was confirmed by extracting peptides from class I MHC molecules of p53 and hdm2 transfectants. Subsequent HPLC purification allowed the reconstitution of CTL lysis by those natural and synthetic HPLC fractions which had an identical retention time. CTL specific for the identified wt p53 and hdm2 epitopes were of sufficiently high avidity to specifically kill a broad range of A2.1 + human tumor, leukemia, and myeloma targets provided that these cells displayed high level p53 and hdm2 protein expression as ascertained by Western blotting. In contrast, a variety of non-transformed human cells, such as PBMC, resting T and B cells, and antigen-activated T lymphocytes, all of them not expressing detectable amounts of p53 and hdm2, were not susceptible to lysis by these CTL. The full length ␣ and ␤ chains of high affinity T cell receptors (TCRs) derived from A2.1-restricted murine CTL clones have been cloned and sequenced. Hu A2.1-positive dendritic cells pulsed with the leukemia-associated hdm2 selfepitope were able to induce peptide-specific autologous human CTL. These autologous CTL, however, appeared to be of low avidity, thereby indicating that the hdm2 epitope does represent a self-tolerogen for high avidity CTL in vivo. Similar observations have been made for A2.1-presented wt p53 CTL epitopes. [1] [2] [3] [4] [5] [6] It has recently been shown in a Mu system that T cell tolerance to widely expressed proteins was also circumvented by raising CTL from MHC-mismatched donors. 7 In a collaborative effort with Hans Stauss (London), peripheral blood mononuclear cells from A2.1-negative and -positive donors were stimulated with (A2.1 + ) T2 cells pulsed with the synthetic hdm2 peptide epitope. Cloning of bulk cultures revealed that CTL clones derived from A2.1-mismatched as opposed to A2.1-matched donors were peptide-specific. A2.1 + and hdm2 overexpressing leukemia and lymphoma cells, in contrast to nontransformed peripheral blood cells, were killed by an allo-A2.1-restricted CTL clone specific for the hdm2 peptide epitope and derived from an A2.1-negative allogeneic donor.
The CD19 signal transduction molecule is expressed by more than 95% of Hu B lymphoid malignancies and is therefore likely to serve as an attractive B cell-associated 
and a 10-mer peptide, both of which were derived from the extracellular domain of the CD19 molecule, demonstrated specific recognition and lysis of EA2/19 as opposed to the parental EA2 transfectants, thereby indicating that these peptides serve as natural A2.1-bound CTL epitopes. Consistent with this finding, A2.1 + EBV-transformed B lymphoblastoid cell lines, as well as B cell-derived lymphoma and leukemia lines were efficiently killed by A2.1-restricted and HuCD19 peptide-specific CTL.
In situations in which the host immune system is devoid of such high avidity, tumor-and leukemia-reactive CTL, the Mu genes for A2.1-restricted and wt p53, hdm2 or HuCD19 epitope-specific TCRs could be transfered into patient T cells. High affinity tumor-and leukemia-specific TCR genes could also be isolated from allo-A2.1-restricted Hu CTL clones. High-affinity TCRs derived from tumorand leukemia-specific A2.1-restricted Tg and Hu CTL could be modified and used to transfer antigen specificity. [8] [9] [10] The most attractive approach is to attach to the TCR an intracellular domain that enables direct signal transduction. 8 This would override the necessity of relying upon appropriate interaction with the endogenous TCR-CD3 complex in order to transduce a stimulatory signal. Hooking up the TCR molecules with the intracellular domains of CD3 ⑀, , 8 or FcR ␥ , or with cytoplasmic tyrosine kinases (Syk, ZAP 70) 11 is supposed to be an attractive approach. The extracellular domains could consist of either a single (sc) or double chain (dc) TCR molecule. In order to prevent competition with endogenous TCR ␣ and ␤ chains and to increase the expression efficiency of the desired TCR specificity, sc TCRs are likely to be of advantage. 8 The designed TCR molecules could also be equipped with an Ig or CD8 hinge (in order to allow the extension of the TCR from the transmembrane region) and short spacers (in order to enhance the three-dimensional flexibility of the TCR molecule).
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Retroviral gene transfer allows efficient transduction of Hu T lymphocytes with both high affinity tumor-and leukemia-specific sc and dc TCRs as well as suitable suicide genes. 10 Crosslinking of transduced Hu T cells by anti-CD3 and anti-CD28 monoclonal antibodies results in short-term clonal expansion required for adoptive transfer into tumor and leukemia patients. Constant TCR regions of human origin could be employed to humanize designer sc and dc TCRs obtained from A2.1-Tg mice, thereby preventing a potential immune reponse directed against sc or dc TCR-transduced human T lymphocytes during therapeutic intervention in vivo.
As another therapeutic option, allo-restricted Hu CTL raised against peptides that are preferentially expressed in transformed cells would be particularly useful for adoptive immunotherapy of cancer and leukemia patients. 12 As these patients may receive hemopoietic stem cell transplants from partially MHC-mismatched donors, it is likely that they would accept injections of MHC-mismatched, donorderived CTL clones specific for tumor-and leukemiaassociated peptide epitopes.
As an alternative, T cells with low avidity for wt p53, hdm2 and CD19-derived peptide antigens as well as residual high avidity CTL precursors that have escaped negative selection could be expanded by a variety of different vaccination strategies including delivery of replicationdeficient recombinant adenoviral vectors or synthetic peptides. Under certain circumstances, such as low tumor burden and high density antigen expression, even the amplification of a low avidity T cell repertoire could be of some therapeutic value. 5 Provided that the peripheral T cell repertoire is not devoid of high avidity CTL specific for tumor-or leukemiaassociated peptide antigens not being expressed intrathymically, TCR technology could be used to express selected high affinity TCRs in hemopoietic stem cells. Depending on the efficiency of hemopoietic stem cell transduction, this would, in theory, give rise to a high frequency of tumor-or leukemia-reactive CTL in the peripheral T cell repertoire.
The identification of wt p53, hdm2, and CD19-derived peptides representing broad-spectrum, cancer-and leukemia-associated CTL epitopes provides the molecular background for p53-, hdm2-, and CD19-directed vaccination strategies and TCR-based immunotherapy of malignant disease.
